




The relative strengths and weaknesses of Xilio Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xilio Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 9.8% points. The greatest weakness of Xilio Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 72% points.

The company's Economic Capital Ratio, given in the ranking table, is 150%, being 63% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	48,127
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	15,957
Liabilities, Non-Current	8,142
Other Assets	6,857
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	2,729
Other Revenues	0
Property and Equipment	5,942
Research and Development	52,136
Selling, General and Administrative Expense	26,997

Output Variable	Value in 1000 USD
Assets	60,926
Liabilities	24,099
Expenses	79,133
Revenues	0
Stockholders Equity	36,827
Net Income	-76,404
Comprehensive Net Income	-76,404
BaseVar	83,444
ECR before Limited Liability	9.1%
Economic Capital Ratio	150%